In the previous head-to-head clinics of Tremfya and Keshanting, Keshanting's advantages in psoriasis were challenged, which was not as good as Tremfya's. In psoriatic arthritis/ankylosing spondylitis, compared with adalimumab, Kesantin has no advantage. Among the indications for rheumatoid arthritis and immune enteritis, Keshanting was directly disqualified because it was not applicable.
Keshanting, also known as Scochizumab injection, is a biological preparation for the treatment of moderate and severe plaque psoriasis in adults. After 5 years of use, it is recommended to continue to use Keshanting according to the doctor's advice, and can be combined with phototherapy for comprehensive treatment.